Clinical Trial

Pulsed-Field Ablation With/Without Electrogram Mapping

Study acronym: PEAK-AF
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
Pulsed field ablation (PFA) has demonstrated favorable safety and efficacy in atrial fibrillation ablation, particularly for pulmonary vein isolation (PVI). However, the optimal PFA-based ablation strategy for non-paroxysmal atrial fibrillation remains uncertain. In addition to anatomical lesion sets such as PVI and posterior wall isolation (PWI), Electrogram Mapping of Key Substrates may allow identification of residual arrhythmogenic areas that contribute to the maintenance of atrial fibrillation. In the investigators' previously completed single-center cohort study, adjunctive ablation targeting key substrates identified by electrogram mapping on top of PVI+PWI was feasible and associated with improved rhythm outcomes. This prospective multicenter randomized controlled study is designed to compare PFA-based PVI+PWI alone versus PVI+PWI plus adjunctive ablation guided by Electrogram Mapping of Key Substrates in patients with non-paroxysmal atrial fibrillation, in order to evaluate the efficacy and safety of this strategy in a broader and more rigorous clinical setting.
Trial Details
NCT Number NCT07541989
Lead Sponsor Xu Liu
Collaborators: Shanghai Chest Hospital of Shanghai Jiao Tong University
Conditions Non-paroxysmal Atrial Fibrillation
Enrollment 300 participants
Start Date 2024-09-30
Primary Completion 2028-05-01 (estimated)
Study Completion 2028-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-21